ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1383

IMPACT of Smoking in the Expression of Periodontitis and Anticitrullinated Protein Antibodies in Rheumatoid Arthritis

Jerián González Febles1, Jorge Luis Garnier Rodríguez2, Fernando Sánchez-Alonso3, Sagrario Bustabad4, Federico Díaz-González5, Mariano Sanz Alonso1 and Beatriz Rodriguez Lozano6, 1Periodontology, Universidad Complutense de Madrid, Madrid, Spain, 2Odontology, Dental Clinic Garnier, S/C Tenerife, Spain, 3Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, 4Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, 5Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 6Rheumatology, Hospital de Canarias, S/C Tenerife, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ACPA, Periodontitis, rheumatoid arthritis (RA) and tobacco use

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Environmental, genetic and epigenetic factors can induce citrullination of structural peptides by the enzyme PAD, which induce anti-citrullinated protein antibodies (ACPA) preceding RA. Among the environmental factors are cigarette smoke, infections, such as P. gingivalis and A. actinomycetemcomitans in periodontitis (PD) and Prevotella copri of intestinal microflora, and silica dust. Given the implication of these two exogenous factors, tobacco and PD in citrullination, and tobacco enhancer factor in PD, we studied: 1. The risk of smoking for developing advanced PD in patients with RA. 2. Possible influence of smoking on the expression of severe PD and ACPA in RA patients.

Methods: Observational, cross-sectional study in RA patients older tan 18yo (ACR/EULAR 2010), with ≥4 teeth, without tooth cleaning nor antibiotic intake 6 months previously. Socio-demographic and anthropometric variables included smoking status, social indicators such as Graffar scale, stress level, and co-morbidities such as diabetes mellitus, dyslipidemia, ischemic cardiovascular disease. Serum ACPA detection: semiquantification Ab IgG against citrullinated peptides (ELISA) with Immunoscan CCPlus®test kit. Euro Diagnostica: positive >25 U/mL; ACPA title stratification: Low (25–75), moderate (76–300) and high (>300). Periodontal parameters: plaque index (PI), Bleeding on probing (Bop), probing pocket depth, recession, clinical attachment level (CAL). CAL loss was categorized according to European Workshop 2005 (Tonetti)1: T level 0 (abscence), TL1 (mild), TL2 (severe). Statistical analysis: t-student, Kruskal Wallis, Chi-cuadrado by Stata program 13.1.

Results: We studied 187 patients, F/M 78.6%/21.4%, mean age 54.4 yo Follow-up time 8.8 yo Rheumatoid Factor positive 74.2%, ACPA positive in 114/168 patients (67.86%). Smoking habit: Current smoker (19.25%), former smoker (24.6%); low socioeconomical status (36.4%)/ relative poverty (33.7%).PD was observed in 97.3%: TL1 52.4%, TL2 44.9%. A “risk gradient” was observed for PD related to smoking habit: former smoker OR 1.62 (95% CI 0.81–3.27),p=0.174; smokers, OR 2.27 (95% CI 1.05– 4.91), p=0.037. When analyzing the influence of smoking on PD development according to ACPA profile, a gradient effect of developing severe PD was observed from former smokers OR 2.37 (IC95% 0.52–7.64) to current smokers OR 6.99 (IC95% 1.53–32.07) (p=0.029) in ACPA(-) patients. This relationship was not observed in ACPA (+) patients (p=0.383).

Conclusion: 1.There is a “risk gradient” to develop PD in RA in relation to past or current exposure to tobacco, so that, although not significant, former smokers are at greater risk than non-smokers, and current smokers have a significant risk 2.3 times higher. 2. This risk gradient is shown in ACPA (-) patients, but not in ACPA (+) patients, which suggests an independent relationship between PD and ACPA (+) RA.


Disclosure: J. González Febles, None; J. L. Garnier Rodríguez, None; F. Sánchez-Alonso, None; S. Bustabad, Gebro, 2; F. Díaz-González, None; M. Sanz Alonso, None; B. Rodriguez Lozano, None.

To cite this abstract in AMA style:

González Febles J, Garnier Rodríguez JL, Sánchez-Alonso F, Bustabad S, Díaz-González F, Sanz Alonso M, Rodriguez Lozano B. IMPACT of Smoking in the Expression of Periodontitis and Anticitrullinated Protein Antibodies in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/impact-of-smoking-in-the-expression-of-periodontitis-and-anticitrullinated-protein-antibodies-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-smoking-in-the-expression-of-periodontitis-and-anticitrullinated-protein-antibodies-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology